Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism01:18

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism

Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Atherosclerosis IV: Nursing Management01:23

Atherosclerosis IV: Nursing Management

Nursing management for a patient with arteriosclerosis involves a comprehensive approach focusing on lifestyle modification, disease monitoring, education, and symptomatic care. Here is an overview of effective nursing strategies:Assessment and Monitoring: Initial and ongoing assessments are crucial. Nurses must document the patient's medical history, including any hypertension, diabetes, hyperlipidemia, and other cardiovascular diseases. Assessments also cover family history and lifestyle...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution01:00

Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Distribution

Drug distribution in the human body is influenced by several factors, including plasma protein concentration, body composition, blood flow, tissue-protein concentration, and tissue fluid pH. Among these, changes in plasma protein concentration and body composition due to aging significantly affect how drugs are distributed within the body. Specifically, aging is associated with a decrease in albumin levels by about 10% and an increase in α1-acid glycoprotein levels. These alterations are not...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneity in Aging: Exploring Grip Strength Variability in Population-Based Age-Sex Cohorts.

The journals of gerontology. Series A, Biological sciences and medical sciences·2026
Same author

Immune aging biomarkers for clinical trials.

Nature medicine·2026
Same author

Delphi-derived Framework for Healthspan-Oriented Care: The Cardiometabolic Health Perspective.

Aging and disease·2026
Same author

Single-cell map of the healthy human immune system across the lifespan reveals unique infant immune signatures.

Nature communications·2026
Same author

p21-senescent cells drive pancreatic islet dysfunction through targetable paracrine signaling in type 2 diabetes.

JCI insight·2026
Same author

Distinct senescent β-cell senotypes differentially drive islet aging and dysfunction.

bioRxiv : the preprint server for biology·2026

Related Experiment Videos

Stroke severity and outcomes for octogenarians receiving statins.

Michael S Phipps1, Neer Zeevi, Ilene Staff

  • 1Stroke Center at Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA. mphipps@calalum.org

Archives of Gerontology and Geriatrics
|July 3, 2013
PubMed
Summary

Pre-exposure to statins (3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors) may offer benefits for elderly patients with acute ischemic stroke (AIS). While not statistically significant, statin use showed trends toward reduced stroke severity and improved short-term outcomes in patients over 80.

Keywords:
3-Hydroxy-3-methylgutaryl-coenzyne A reductase inhibitorElderlyIschemic strokeStatinStroke severity

Related Experiment Videos

Area of Science:

  • Geriatric Neurology
  • Cardiovascular Research
  • Stroke Medicine

Background:

  • Pre-exposure to statins is associated with improved outcomes in acute ischemic stroke (AIS).
  • The efficacy and safety of pre-admission statin use in patients aged 80 and older with AIS remain largely unknown.
  • Elderly populations often have complex comorbidities that may influence stroke outcomes.

Purpose of the Study:

  • To investigate the association between pre-admission statin use and clinical outcomes in patients aged 80 years or older with AIS.
  • To evaluate the safety of pre-admission statin use, specifically the risk of subsequent intracerebral hemorrhage (ICH).
  • To determine if statin use impacts stroke severity and short-term functional outcomes in this elderly cohort.

Main Methods:

  • Retrospective review of 804 patients aged ≥80 with AIS from a tertiary stroke center registry.
  • Assessment of pre-admission statin use, demographics, vascular risk factors, and comorbidities.
  • Multivariable logistic regression analysis to evaluate primary outcomes (NIHSS, in-hospital mortality/hospice discharge) and secondary outcomes (ICH, modified Barthel Index at 3 months).

Main Results:

  • Patients on pre-admission statins were younger and had more vascular risk factors but were less likely to receive IV tPA.
  • A trend towards lower stroke severity (NIHSS > 16: 21.9% vs 27.6%) and improved short-term outcomes (mortality/hospice: 22.8% vs 27.6%) was observed in statin users, though not statistically significant.
  • No significant difference in subsequent ICH (1.2% vs 1.9%) or a trend towards less disability at 3 months (mBI: 27.5% vs 35.7%) was found.

Conclusions:

  • Pre-admission statin use did not significantly improve outcomes in patients ≥80 with AIS but showed a trend toward reduced stroke severity and better short-term results.
  • The findings suggest that statins are likely safe in elderly stroke patients and do not appear to increase the risk of intracerebral hemorrhage.
  • Further prospective studies are warranted to confirm the potential benefits of statins in this specific patient population.